Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?
DOI:
https://doi.org/10.58931/crt.2024.1252Abstract
As 2024 continues to evolve, so do treatment recommendations for the management of spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). From a Canadian perspective, we eagerly await the publication of the Canadian Rheumatology Association (CRA)/Spondyloarthritis Research Consortium of Canada (SPARCC) Living Treatment Recommendations for the Management of Axial Spondyloarthritis (axSpA), currently in press. Until these recommendations for axSpA treatment with a Canadian perspective arrive – where are we now?
References
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285–1299. doi: 10.1002/acr.24025 DOI: https://doi.org/10.1002/acr.24025
Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34. doi: 10.1136/ard-2022-223296 DOI: https://doi.org/10.1136/ard-2023-223937
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi: 10.1136/bmj.39489.470347.AD DOI: https://doi.org/10.1136/bmj.39489.470347.AD
Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine:The Oxford 2009 levels of evidence. [Updated: 2024, Cited: 14 Jun 2024]. Available at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-forevidence- based-medicine-levels-of-evidence-march-2009.
Sinnappan S, Forte A, Ermann J. Axial spondyloarthritis treatment recommendations and disease activity monitoring in clinical practice: results of an online survey. J Rheumatol. 2024;51(5):472–478. doi: 10.3899/jrheum.2023-0894. DOI: https://doi.org/10.3899/jrheum.2023-0894
Akl EA, Meerpohl JJ, Elliott J, Kahale LA, Schünemann HJ, Living Systematic Review Network. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol. 2017;91:47–53. doi: 10.1016/j.jclinepi.2017.08.009 DOI: https://doi.org/10.1016/j.jclinepi.2017.08.009
Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al. Living systematic review: 1. Introduction-the why, what, when, and how. J Clin Epidemiol. 2017;91:23–30. doi: 10.1016/j.jclinepi.2017.08.010 DOI: https://doi.org/10.1016/j.jclinepi.2017.08.010
Hazlewood GS, Pardo JP, Barnabe C, Schieir O, Barber CEH, Proulx L, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs [version 2.1]. [Internet]. [cited 25 Nov 2023]. Available from: https://app.magicapp.org/#/guideline/7413
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Rheumatology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.